FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 2243 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis. PMID 42350220 · Clin Genitourin Cancer · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Determining the cutpoint of a continuous predictive biomarker via Bayesian sensitive subpopulation finding. PMID 42228058 · J Biopharm Stat · 2026-Jun-02 The record describes a Phase III randomized trial in advanced breast cancer with a time-to-event endpoint, but the publication is a methodological paper applying a new statistical method to trial data, not the original trial report. It does not explicitly state a drug intervention, and it is not a formal result report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer. PMID 42229584 · Ann Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial. PMID 42224659 · JAMA Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. PMID 42224490 · JAMA · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial. PMID 42223137 · J Clin Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. PMID 42223130 · J Clin Oncol · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer. PMID 42219560 · Cancer Res Commun · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 11 Panel · risk visible |
| Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis. PMID 42338692 · Liver Cancer · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. PMID 42306064 · Hemasphere · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 3 Figure · 11 Panel · risk unclear |
| Hepatic Arterial Infusion Chemotherapy plus either Toripalimab or Sorafenib as First-line Therapy for Locally Advanced Hepatocellular Carcinoma: A Non-comparative, Randomized Phase 2 Trial. PMID 42266185 · MedComm (2020) · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 2 Panel · risk visible |
| Safety-Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials. PMID 42186850 · Stat Med · 2026-Jun The record is a methodological study proposing and simulating a new trial design (SAFER), not an original formal-result report of a specific Phase III trial. While it references a Phase III trial (CAPP-IT) and is oncology-related, it does not present primary efficacy results (time-to-event or otherwise) for that or any trial. |
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Palbociclib in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review. PMID 42173733 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Predicting Radiation-Induced Esophagitis in Locally Advanced NSCLC Using Baseline Clinical Factors: A Model From the Japan Lung Cancer Society Integrated Phase II-III Database. PMID 42173719 · Clin Lung Cancer · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Smoldering Multiple Myeloma: From Clinical to Immunogenomic Risk Stratification and Therapeutic Implications of Early Intervention. PMID 42172562 · Am Soc Clin Oncol Educ Book · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Regulatory approval of new oncology drugs, 2020-2024: A comparative analysis of FDA, EMA, and ANVISA. PMID 42142604 · J Cancer Policy · 2026-Jun The record is a comparative analysis of oncology drug approvals by regulatory agencies (FDA, EMA, ANVISA), not an original report of a randomized clinical trial with a time-to-event efficacy endpoint. It does not meet the criterion of being an original result report of a trial. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol. PMID 42125606 · ILIVER · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma. PMID 41991383 · Urol Oncol · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France. PMID 41973335 · Drugs Real World Outcomes · 2026-Jun The record describes a real-world descriptive analysis of an early access program for olaparib combination therapy in prostate cancer. While it mentions the PROpel Phase III trial as the basis for approval, it does not report the results of that trial. The study itself is non-randomized, does not present time-to-event efficacy endpoints, and is not an original report of a randomized trial result. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated versus conventional IMRT in unfavorable intermediate- and high-risk prostate cancer: A phase II comparative study of PSA kinetics, dosimetric and toxicity outcomes. PMID 41967586 · Fr J Urol · 2026-Jun The record describes a Phase II randomized trial, not a Phase III or IIIb trial as required. Although it meets other criteria (oncology, human, randomized, time-to-event endpoint, drug intervention), the phase is insufficient for eligibility. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. PMID 41957135 · Br J Cancer · 2026-Jun The record describes a secondary analysis of individual patient data from multiple randomized phase II/III trials of concurrent chemoradiotherapy (cCRT) for NSCLC. While it includes oncology, human subjects, randomized trials, phase III/IIIb studies, and time-to-event endpoints (PFS, OS), the drug intervention is not explicitly established as a defining factor of the analysis (cCRT is a regimen, but the specific drug intervention is not detailed or contrasted with a non-drug control). Furthermore, this is a pooled analysis of multiple trials, not the primary result report of a single randomized trial, making it a secondary analysis rather than the original definitive report required. |
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy for obstructive colon cancer derived by a stoma: Study protocol of the FRENCH-01 randomized phase III trial (COnCERTO Trial). PMID 41945039 · Dig Liver Dis · 2026-Jun 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The role of circulating tumor DNA in precision adjuvant therapy for colorectal cancer: a scoping review. PMID 41935608 · J Gastrointest Surg · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Host-directed therapy for tuberculosis: Repurposed drugs toward global tuberculosis elimination. PMID 41856464 · Int J Infect Dis · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PMID 41840238 · Nat Med · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 8 Panel · risk visible |
| Immunotherapy failure in glioblastoma: A systematic review and meta-analysis of randomized controlled trials. PMID 41839399 · Crit Rev Oncol Hematol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Active immunization strategies in glioblastoma - clinical outcomes and effect modifiers for dendritic vaccines and adoptive cell therapies: a systematic review. PMID 41833230 · J Clin Neurosci · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307. PMID 41811656 · Oncol Ther · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 3 Figure · 6 Panel · risk visible |
| Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis. PMID 41694651 · Liver Cancer · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal and gastric peritoneal metastases: Where are we today? PMID 41547607 · J Visc Surg · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. PMID 41454190 · Ann Surg Oncol · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 4 Figure · 12 Panel · risk visible |
| Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. PMID 42497381 · J Clin Oncol · 2026-Jul-24 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy. PMID 42496653 · Oncologist · 2026-Jul-24 This is a Phase III, randomized, drug-intervention trial in advanced breast cancer, but it reports on visual safety and patient-reported outcomes, not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet the inclusion criteria for a time-to-event efficacy report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. PMID 42483956 · Expert Rev Anticancer Ther · 2026-Jul-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1. PMID 42492022 · J Clin Oncol · 2026-Jul-23 Trial compares two radiotherapy fractionation schedules (drug-free intervention), not a drug-containing regimen. Meets all other criteria (Phase III, randomized, human oncology, time-to-event efficacy endpoints with original results) but fails the drug intervention requirement. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial. PMID 42492015 · J Clin Oncol · 2026-Jul-23 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Robotic Thoracic Surgery After Neoadjuvant Chemo-Immunotherapy for NSCLC: A Narrative Review. PMID 42512424 · Cancers (Basel) · 2026-Jul-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. PMID 42486133 · Lancet · 2026-Jul-22 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
S
B
|
严格 v3 独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials. PMID 42485700 · ESMO Open · 2026-Jul-22 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT). PMID 42485106 · Clin Cancer Res · 2026-Jul-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Extent of Lymphadenectomy in Esophageal Cancer Surgery: Unresolved Issues in Prophylactic 3-Field Dissection. PMID 42482330 · J Chest Surg · 2026-Jul-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial. PMID 42483812 · Biomol Biomed · 2026-Jul-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Systematic review and adjusted indirect comparison of first-line immune checkpoint inhibitors in metastatic colorectal cancer. PMID 42481259 · Farm Hosp · 2026-Jul-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. PMID 42511798 · Int J Mol Sci · 2026-Jul-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study. PMID 42477876 · J Natl Cancer Inst · 2026-Jul-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| First-Line Immunotherapy Versus Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies. PMID 42474934 · J Gastrointest Cancer · 2026-Jul-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors. PMID 42473802 · Future Oncol · 2026-Jul-20 The record describes a Phase III, randomized trial protocol for a novel monoclonal antibody in a rare soft tissue tumor. It is a human oncology study with a drug intervention. However, it is a protocol/registration summary without reported efficacy results, and no primary or secondary time-to-event endpoint (such as OS, PFS, DFS, or HR) is mentioned. Therefore, it does not meet the criteria for an original formal-result report of a completed trial. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Minimal incision-assisted endoscopic versus conventional open breast-conserving surgery: A multicentre randomized clinical trial. PMID 42497645 · Breast · 2026-Jul-19 The study is a phase III randomized controlled trial in oncology (breast cancer), but it compares surgical techniques (minimal incision-assisted endoscopic vs. conventional open breast-conserving surgery) and does not involve a drug-containing intervention. The primary and secondary endpoints are patient-reported outcomes (scar satisfaction, QoL) and surgical metrics, not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study. PMID 42472670 · Am J Hematol · 2026-Jul-19 The study is a randomized Phase III trial with a drug intervention (eltrombopag) and time-to-event endpoints (OS, DFS, EFS), but it is for severe aplastic anemia, a non-oncology hematologic disorder, not a malignant neoplasm. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer. PMID 42467210 · Clin Cancer Res · 2026-Jul-17 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |